58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
Titel:
58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
Auteur:
Marmé, F. Hanusch, C. Furlanetto, J. Morris, P. Link, T. Denkert, C. Fasching, P.A. Jackisch, C. Antolín, S. Solbach, C. Aftimos, P. Huober, J. Untch, M. Balic, M. Reinisch, M. Blohmer, J-U. Gonçalves, A. Rey, J. Büchele, T. Loibl, S.